Evidence in Action: Driving Oncology Asset Valuation for an Informed Investment

A healthcare division of a private equity firm was evaluating the acquisition of oncology assets from a biopharmaceutical company. A rapid, evidence-based valuation of the opportunity and forecast model was required.

• Delivered actionable insights enabling refinement of the asset offer
• The project resulted in a positive investment committee endorsement
• Enhanced credibility of the investor team with biotech sellers and co-investors

• Conducted scientific and commercial due diligence on multiple oncology assets
• Built dynamic forecast models incorporating market evolution, clinical potential, and competitive landscape
• Provided risk-adjusted value estimates to guide investment decisions